Business Context and Reporting Period
Company: Elicio Therapeutics, Inc. (ELTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Elicio is a clinical-stage biotechnology company developing lymph node-targeted immunotherapies for cancer, specifically focusing on mutant KRAS (mKRAS) driven cancers such as pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). The company utilizes its proprietary Amphiphile (AMP) technology to deliver payloads to lymph nodes to stimulate robust T-cell responses.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(39.6) | $(51.9) |
| Research & Development Expenses | $(24.9) | $(33.7) |
| General & Administrative Expenses | $(12.8) | $(11.3) |
| Cash and Cash Equivalents (Year End) | $18.6 | $17.6 |
| Accumulated Deficit | $(233.7) | $(194.1) |
| Long-Term Debt (Net) | $9.4 | $20.0 |
| Warrant Liabilities | $2.6 | $2.8 |
Note: The company has no product revenue. Expenses are primarily driven by clinical trial costs and personnel.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 23.8% to $39.6 million in 2025 from $51.9 million in 2024. This improvement was driven by a 26.0% decrease in R&D expenses and a significant reduction in "Other Expense" (primarily changes in fair value of warrant liabilities).
- R&D Expense Decline: R&D expenses dropped $8.8 million, attributed to lower clinical costs as patients in the Phase 2 AMPLIFY-7P study progressed into the observation phase.
- Debt Restructuring: In March 2025, the company converted a $20.0 million Senior Secured Convertible Note into common stock. In June 2025, the company issued a new $10.0 million Senior Secured Promissory Note due in 2028.
- Capital Raises: The company raised approximately $34.5 million in net proceeds during 2025 through At-The-Market (ATM) offerings ($16.2 million), a registered direct offering ($9.2 million), and the new promissory note ($9.9 million).
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- AMPLIFY-7P (Phase 2): Enrollment for the randomized Phase 2 trial of ELI-002 7P in mKRAS-driven PDAC was completed in December 2024. In August 2025, the Independent Data Monitoring Committee (IDMC) recommended continuing the trial to the final event-driven disease-free survival (DFS) analysis without modifications, confirming a favorable safety profile. The final analysis is anticipated in the first half of 2026.
- Immunogenicity Data: In September 2025, the company reported robust mKRAS-specific T-cell responses in 99% of evaluable patients in the Phase 2 trial. Antigen spreading to patient-specific neoantigens was observed in 87% of evaluated patients in December 2025.
- Future Pipeline: Preclinical programs ELI-007 (mutant BRAF) and ELI-008 (mutant TP53) are advancing. An Investigator-Initiated Trial (IIT) for neoadjuvant ELI-002 7P is expected to commence in the first half of 2026.
Liquidity and Going Concern
The company has raised substantial doubt regarding its ability to continue as a going concern. As of the filing date, management believes cash on hand ($18.6 million) is sufficient to fund operations into the third quarter of 2026. The company will require additional financing to continue development beyond this period. Failure to secure capital could force the company to delay, limit, or terminate research programs.
Key Risks
- Capital Requirements: High dependence on external equity or debt financing; potential for dilution or restrictive covenants.
- Clinical Uncertainty: Risk that the Phase 2 trial may not meet primary endpoints or that safety issues arise.
- Intellectual Property: Substantial dependence on patents licensed from MIT; risk of license termination or invalidation.
- Manufacturing: Reliance on third-party contract manufacturing organizations (CMOs), some located in China, subject to geopolitical and supply chain risks.
Investor Verification Checklist
- Cash Runway: Verify the specific burn rate and confirm the "third quarter of 2026" liquidity estimate against current cash balances and operating expenses.
- Debt Covenants: Review the terms of the June 2025 Promissory Note ($10M) for covenants, interest rates (Prime + 5%, capped at 12.5%), and collateral requirements (first priority lien on assets and IP).
- MIT License Obligations: Confirm the status of milestone payments and annual maintenance fees owed to MIT, noting the potential aggregate liability of $26.2 million if all milestones are met.
- Warrant Liability Classification: Monitor the classification of outstanding warrants (liability vs. equity) as changes in fair value significantly impact reported net loss.
- Phase 2 Trial Timeline: Track the event accrual rate for the AMPLIFY-7P trial to validate the projected "first half of 2026" readout date.